8-K: Agilon Health Reports Q3 2024 Results, Revenue Up 28% but Profitability Impacted by Risk Adjustments

Agilon Health's third quarter results show a 28% revenue increase to $1.45 billion, but profitability was negatively impacted by lower-than-expected risk adjustments and higher medical expenses.

Summary

• Agilon Health reported a 28% increase in revenue to $1.45 billion for the third quarter of 2024, compared to $1.14 billion in the same period last year.
• Medicare Advantage membership grew by 37% year-over-year to 525,000 members, while total members on the agilon platform increased by 39% to 657,000.
• The company experienced a negative gross profit of $64 million in Q3 2024, a significant drop from a positive $37 million in Q3 2023.
• Net loss for the quarter was $118 million, compared to a net loss of $31 million in the prior year.
• Medical margin was negative $58 million, a decrease from a positive $111 million in the same quarter of 2023.
• Adjusted EBITDA loss was $96 million, compared to a positive $6 million in the third quarter of 2023.
• The company's results were negatively impacted by $60 million in prior year development, $65 million reduction in estimated 2024 risk adjustment, and $25 million in higher current year medical expenses.
• Agilon Health is exiting two unprofitable partnerships and select payor contracts by the end of 2024 to strengthen its business.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with strong revenue and membership growth offset by significant losses and downward revisions in guidance. The proactive steps to exit unprofitable partnerships are a positive, but the overall sentiment is negative due to the financial underperformance.

Positives

• Total revenue increased by 28% year-over-year, reaching $1.45 billion.
• Medicare Advantage membership grew by 37% year-over-year, reaching 525,000 members.
• Total members on the agilon platform increased by 39% year-over-year, reaching 657,000.
• The company is taking proactive steps to exit unprofitable partnerships and contracts to improve future profitability.

Negatives

• Gross profit was negative $64 million, a significant decrease from the positive $37 million in the same quarter last year.
• Net loss was $118 million, a substantial increase from the $31 million loss in the third quarter of 2023.
• Medical margin was negative $58 million, a significant drop from the positive $111 million in the same period last year.
• Adjusted EBITDA was a loss of $96 million, compared to a profit of $6 million in the third quarter of 2023.
• The company experienced a $60 million negative impact from prior year development, primarily related to risk adjustment and Part D medical expenses.
• A $65 million reduction in estimated 2024 risk adjustment further negatively impacted results.
• Higher current year medical expenses added $25 million to the negative impact.

Risks

• The company's financial results were significantly impacted by lower-than-expected risk adjustments and higher medical expenses.
• Prior year development, particularly related to risk adjustment and Part D, negatively affected profitability.
• The company is facing challenges in the Medicare Advantage environment, requiring proactive measures to strengthen execution.
• Exiting unprofitable partnerships and contracts may lead to short-term disruptions.
• The company's guidance for 2024 has been revised downwards due to the Q3 results and updated cost trends.
• There is uncertainty around certain items that may impact gross profit or net income (loss), including non-cash stock-based compensation.

Future Outlook

The company has updated its full-year 2024 guidance to reflect Q3 results and updated cost trends for Q4, with medical margin guidance including approximately $100 million of negative prior period development. The guidance does not reflect the impact of actions the company is currently undertaking or plans to take before the close of the fiscal year. The company expects to have between 526,000 and 528,000 Medicare Advantage members by the end of 2024.

Management Comments

• Steve Sell, chief executive officer, stated that the company's membership is growing across its 26 partnerships, but also highlighted the need to strengthen execution and manage the challenging Medicare Advantage environment.
• Management has initiated steps to exit two unprofitable partnerships and other payor contracts by the end of 2024 to strengthen the business.

Industry Context

The results reflect challenges in the Medicare Advantage market, including risk adjustment and medical cost pressures, which are impacting multiple players in the healthcare sector. Agilon's actions to exit unprofitable partnerships and contracts are indicative of a broader trend of companies re-evaluating their strategies in response to these challenges.

Comparison to Industry Standards

• Agilon's 37% growth in Medicare Advantage membership is strong compared to the industry average, but the negative medical margin and adjusted EBITDA are concerning.
• Companies like Oak Street Health and Cano Health have also faced challenges in managing medical costs and risk adjustments, indicating a broader industry trend.
• Agilon's decision to exit unprofitable partnerships is similar to actions taken by other healthcare providers to optimize their portfolios.
• The negative prior year development of $60 million is a significant issue, and it is important to compare this to other companies in the sector to see if this is an industry wide issue or specific to Agilon.

Stakeholder Impact

• Shareholders will be negatively impacted by the lower-than-expected financial results and revised guidance.
• Physician partners may be affected by the exit of unprofitable partnerships and changes in payor contracts.
• Employees may experience uncertainty due to the company's restructuring efforts.
• Customers (members) may see changes in their healthcare options due to the partnership exits.

Next Steps

• The company will exit two unprofitable partnerships and select payor contracts by the end of 2024.
• The company will focus on strengthening execution within its platform and proactively managing the Medicare Advantage environment.
• The company will continue to monitor and adjust its cost trends for the fourth quarter of 2024.

Key Dates

Keywords

Medicare Advantage, Risk Adjustment, Medical Margin, Adjusted EBITDA, Healthcare, Partnerships, Revenue, Membership, Profitability, Financial Results